Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $5,000 | $0 | $0 | $0 |
| Gross Profit | -$5,000 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $40,520 | $38,724 | $52,151 | $45,912 |
| G&A Expenses | $12,180 | $15,316 | $18,785 | $17,010 |
| SG&A Expenses | $12,180 | $15,316 | $18,785 | $17,010 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $52,700 | $54,040 | $70,936 | $62,922 |
| Operating Income | -$57,700 | -$54,040 | -$70,936 | -$62,922 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $945 | $1,334 | $3,049 | $4,103 |
| Pre-Tax Income | -$56,755 | -$52,706 | -$67,887 | -$58,819 |
| Tax Expense | $0 | $25 | $105 | $0 |
| Net Income | -$56,755 | -$52,731 | -$67,992 | -$58,819 |
| % Margin | – | – | – | – |
| EPS | -0.35 | -0.33 | -0.42 | -0.37 |
| % Growth | -6.1% | 21.4% | -13.5% | – |
| EPS Diluted | -0.35 | -0.33 | -0.42 | -0.37 |
| Weighted Avg Shares Out | 161,838 | 161,691 | 161,451 | 160,984 |
| Weighted Avg Shares Out Dil | 161,838 | 161,691 | 161,451 | 160,984 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,685 | $1,814 | $3,074 | $4,088 |
| Interest Expense | $747 | $0 | $0 | $0 |
| Depreciation & Amortization | $23 | $19 | $157 | $157 |
| EBITDA | -$55,985 | -$54,021 | -$70,779 | -$62,765 |
| % Margin | – | – | – | – |